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Abstract
The aim of this prospective observational study was to determine the accuracy of American Thoracic Society (ATS)/Infectious Diseases
Society of America (IDSA) criteria in predicting infection or colonization related to multidrug-resistant (MDR) bacteria at intensive-care
unit (ICU) admission. MDR bacteria were deﬁned as methicillin-resistant Staphylococcus aureus, ceftazidime-resistant or imipenem-resis-
tant Pseudomonas aeruginosa, Acinetobacter baumannii, Stenotrophomonas maltophilia, and extended-spectrum b-lactamase-producing Gram-
negative bacilli. Screening for MDR bacteria (using nasal and rectal swabs and tracheal aspirates from intubated patients) was performed
at ICU admission. Risk factors for infection or colonization with MDR bacteria at ICU admission were determined using univariate and
multivariate analyses. The accuracy of ATS/IDSA criteria in predicting infection or colonization with these bacteria at ICU admission
was calculated. Eighty-three (13%) of 625 patients were infected or colonized with MDR bacteria at ICU admission. Multivariate analysis
allowed identiﬁcation of prior antimicrobial treatment (OR 2.3, 95% CI 1.2–4.3; p 0.008), residence in a nursing home (OR 2,
95% CI 1.1–3.7; p <0.001), and prior hospitalization (OR 3.9, 95% CI 1.7–8.8; p <0.001) as independent predictors of infection or colo-
nization with MDR bacteria at ICU admission. Although sensitivity (89%) and negative predictive values (96%) were high, low speciﬁcity
(39%) and a positive predictive value (18%) were found when ATS/IDSA criteria were used in predicting infection or colonization with
MDR bacteria at ICU admission. In patients with pneumonia, adherence to guidelines was associated with increased rates of appropriate
initial antibiotic treatment and de-escalation. ATS/IDSA criteria had an excellent negative predictive value and a low positive predictive
value concerning infection or colonization with MDR bacteria at ICU admission.
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Introduction
The prevalence of multidrug-resistant (MDR) bacteria is
increasing worldwide [1]. MDR bacteria are common in inten-
sive-care unit (ICU) patients. Although the majority of these
bacteria are acquired during the ICU stay, a large number of
patients are admitted to the ICU with healthcare-associated
infections related to MDR bacteria [2,3]. Inappropriate initial
antimicrobial treatment is frequently associated with MDR
bacteria [4,5]. Inappropriateness of initial antibiotic treatment
is an important risk factor for mortality, increased duration of
mechanical ventilation and ICU stay, higher rates of recur-
rence of infection and higher costs [6–9].
Recently, the American Thoracic Society (ATS) and the
Infectious Diseases Society of America (IDSA) published
guidelines for patients with healthcare-associated pneumonia
[10]. According to these guidelines, patients with risk factors
for pneumonia related to MDR bacteria should receive
broad-spectrum antimicrobial treatment. In addition, de-esca-
lation should be performed, if possible, at days 2–3, accord-
ing to microbiological results. Although these guidelines
were written for the management of patients with health-
care-associated pneumonia, risk factors for multidrug resis-
tance are similar with respect to other infections, such as
bloodstream infections [3]. Identifying patients with coloniza-
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tion or infection related to MDR bacteria would be helpful
in guiding initial antibiotic treatment and the application of
isolation measures in order to prevent transmission of MDR
bacteria.
To our knowledge, the accuracy of ATS/IDSA criteria in
predicting infection or colonization related to MDR bacteria
at ICU admission has not been assessed. We hypothesized
that these criteria would be sensitive in identifying infection
or colonization with MDR bacteria and that the speciﬁcity of
these criteria would be low because of the large number of
patients with risk factors for infection or colonization related
to MDR bacteria at ICU admission. Therefore, we per-
formed this prospective observational study to determine
predictors of MDR bacteria at ICU admission and the accu-
racy of ATS/IDSA criteria in predicting infection or coloniza-
tion with these bacteria at ICU admission.
Patients and Methods
Study design
This prospective observational cohort study was conducted in
a 30-bed ICU from December 2006 to December 2007. No
informed consent was required by the local Institutional Review
Board because of the non-interventional design of the study. All
patients hospitalized in the ICUwere eligible for this study.
Study population
The infection control policy included isolation techniques, rou-
tine screening for MDR bacteria, written antibiotic treatment
protocols, and continuous surveillance of nosocomial infec-
tions. In immunocompetent patients, isolation techniques were
used for all patients at ICU admission until receipt of screening
results. Thereafter, these techniques were applied for all
patients with infection or colonization due to MDR bacteria.
Preventive isolation techniques were applied for all immuno-
suppressed patients. These techniques included protective
gowns and glove usage associated with adequate hand hygiene,
achieved by using an alcohol-based hand rub formulation before
and after patient contacts. Routine screening for MDR bacteria
was performed for all patients at ICU admission and weekly
thereafter. This screening included nasal and anal swabs. In addi-
tion, tracheal aspirates were recovered from intubated or tra-
cheotomized patients. Screening of MDR bacteria has been
performed in our ICU as a part of infection control policy, and
not for the purpose of this study. Microbiological cultures of
other specimens were performed according to clinical status.
The Antimicrobial treatment protocol for community-acquired
pneumonia and healthcare-associated pneumonia was based on
recent ATS/IDSA recommendations [10,11].
Data collection and deﬁnitions
All data concerning patient characteristics at ICU admission
and during ICU stay were prospectively collected.
MDR bacteria were deﬁned as methicillin-resistant Staphylo-
coccus aureus (MRSA), ceftazidime-resistant or imipenem-resis-
tant Pseudomonas aeruginosa, Acinetobacter baumannii,
Stenotrophomonas maltophilia and extended-spectrum b-lac-
tamase-producing Gram-negative bacilli. During the study per-
iod, no vancomycin-resistant Enterococcus or community-
acquired MRSA strain was isolated in the ICU. Pneumonia was
deﬁned by the presence of new or progressive radiographi-
cally documented inﬁltrates associated with two of the follow-
ing ﬁndings: (i) temperature >38.5C or <36.5C; (ii)
leukocyte count >10 000/lL or <1500/lL; and (iii) purulent
sputum or tracheal aspirate [10]. Microbiological conﬁrmation
of pneumonia was deﬁned as bronchoalveolar lavage or tra-
cheal aspirate with ‡104 CFU/mL and ‡106 CFU/mL, respec-
tively. Pneumonia was classiﬁed as community-acquired,
healthcare-associated or hospital-acquired according to ATS/
IDSA guidelines [10,11]. Other infections were deﬁned
according to the modiﬁed CDC criteria [12]. Prior antibiotic
treatment was deﬁned as any antibiotic treatment during the
3 months preceding ICU admission. Prior hospitalization was
deﬁned as hospitalization for 2 days or more during the pre-
ceding 3 months. Patients at risk for colonization or infection
with MDR bacteria according to ATS/IDSA criteria were
deﬁned as those patients to whom any of the following criteria
applied: current hospitalization of 5 days or more, prior antibi-
otic therapy, prior hospitalization, residence in a nursing home
or extended-care facility, home infusion therapy within 30
days, chronic dialysis within 30 days, home wound care, family
member with an MDR pathogen, and immunosuppression.
Antimicrobial therapy was considered to be appropriate when
at least one antibiotic active in vitro against all causative organ-
isms was administered to treat infection. De-escalation was
deﬁned as changing the use of multiple agents to a single agent
if P. aeruginosa was not present, or changing from a broad-
spectrum to a narrow-spectrum agent on the basis of culture
data [13]. In patients with pneumonia, the initial antibiotic regi-
men was considered to adhere to ATS/IDSA guidelines when
the antibiotics chosen by the attending physician corre-
sponded to the recommendations of these guidelines [10,11],
regardless of any additional antibiotic received. The McCabe
score [14], chronic obstructive pulmonary disease [15] and
immunosuppression [16] were as deﬁned elsewhere.
Statistical methods
SPSS 11.5 software (SPSS, Chicago, IL, USA) was used for
data analysis. Results are presented as numbers (percentage)
for categorical variables. The distribution of quantitative
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variables was tested. Normally and abnormally distributed
quantitative variables are presented as mean ± standard devi-
ation and median (25th–75th interquartiles), respectively. All
p-values were two-tailed. The statistical signiﬁcance was set
at p <0.05.
Univariate analysis was used to determine factors associ-
ated with ICU-acquired infection. Qualitative variables were
compared using the Pearson chi-square test or Fisher’s exact
test, as appropriate. Quantitative variables were compared
using the Mann–Whitney U-test or the Student t-test, as
appropriate.
Multivariate analysis was used to determine factors inde-
pendently associated with ICU-acquired infection. All predic-
tors showing an association at p <0.1 with infection or
colonization caused by MDR bacteria in univariate analysis
were incorporated in the multivariate logistic regression
analysis. Potential interactions were tested. ORs and
95% CIs were calculated, as well as the Hosmer–Lemshow
goodness-of-ﬁt.
The accuracy of ATS/IDSA criteria in predicting infection
or colonization with MDR bacteria at ICU admission was
determined in all patients and in the subgroups of patients
with suspected infection, microbiologically conﬁrmed infec-
tion, suspected pneumonia, and microbiologically conﬁrmed
pneumonia.
Results
Among the 625 consecutive patients included in this study,
83 (13%) were colonized (50%) or infected (49%) with MDR
bacteria at ICU admission; 383 of 625 (61%) had a suspected
infection at ICU admission, of whom 223 (58%) were sus-
pected to have pneumonia. One hundred and forty-six (23%)
patients had a microbiologically conﬁrmed infection, and of
those, 88 (60%) had pneumonia. Among the 223 patients
with suspected pneumonia, 110 (49%) had community-
acquired pneumonia, 79 (35%) had hospital-acquired pneu-
monia, and 34 (15%) had healthcare-associated pneumonia.
Patient characteristics are presented in Table 1. Four hun-
dred and ninety-six (79%) patients received mechanical venti-
lation. The median duration of mechanical ventilation was
8 days (interquartile range 2–20 days), and the median length
of ICU stay was 13 days (interquartile range 6–26 days).
Two hundred and fourteen (34%) patients died in the ICU.
Risk factors for colonization or infection with bacteria at
ICU admission are presented in Table 1. The microbiological
results are presented in Tables 2 and 3.
The results concerning the accuracy of ATS/IDSA criteria
in predicting colonization or infection with MDR bacteria at
ICU admission are presented in Table 4. At ICU admission,
402 of 625 (64%) patients had at least one risk factor for
MDR bacteria according to ATS/IDSA guidelines. Among
patients with suspected infection, 307 of 383 (80%) had at
least one risk factor for infection with MDR bacteria accord-
ing to ATS/IDSA guidelines.
In patients with microbiologically conﬁrmed infection, ini-
tial antimicrobial treatment was appropriate in 122 of 146
(84%) patients, and in 74 of 88 (84%) patients with pneumo-
nia. The rate of appropriate initial antimicrobial treatment
was lower in patients with infection caused by MDR bacteria
than in patients with infection caused by other bacteria (28
of 41 (68%) vs. 94 of 105 (90%) patients; p 0.004, OR 0.2,
95% CI 0.1–0.6).
In patients with pneumonia, adherence to ATS/IDSA
guidelines was associated with a signiﬁcantly higher rate of
appropriate initial antibiotic treatment (71 of 76 (93%) vs.
two of 12 (17%) patients; p <0.001, OR 71, 95% CI 12–416).
However, no signiﬁcant difference was found in mortality
rates between patients treated according to ATS/IDSA guide-
lines and patients not treated according to these these guide-
lines (28 of 76 (37%) vs. six of 12 (50%); p 0.582).
De-escalation was performed in 41 of 383 (11%) patients
with suspected infection and in 25 of 223 (11%) patients with
suspected pneumonia. De-escalation was signiﬁcantly more
frequently performed in patients with appropriate initial anti-
microbial treatment of infections than in patients with inap-
propriate initial antimicrobial treatment(33 of 122 (27%) vs.
0 of 24; p 0.001; OR 1.3, 95% CI 1.2–1.5). In patients with
suspected pneumonia, adherence to ATS/IDSA guidelines
was associated with a higher rate of de-escalation (25 of 184
(14%) vs. 0 of 39; p <0.001, OR 1.1, 95% CI 1–1.2).
Discussion
Whereas the sensitivity and negative predictive value were
high, low speciﬁcity and a positive predictive value were
found for ATS/IDSA criteria in predicting infection or colo-
nization with MDR bacteria at ICU admission. This result
suggests that when initial antibiotic treatment is based on
these criteria, the probability of providing appropriate
antibiotic treatment is high. Because of the low positive
predictive value, a large proportion of patients with
infection caused by bacteria other than MDR would
receive broad-spectrum initial antibiotic treatment. In fact,
80% of patients with suspected infection at ICU admission
had at least one risk factor for infection or colonization
with MDR bacteria. However, only 10% of these patients
had a microbiologically conﬁrmed infection with MDR
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bacteria. Therefore, de-escalation is mandatory in these
patients in order to prevent subsequent emergence of
MDR bacteria.
At ICU admission, adherence to ATS/IDSA guidelines was
associated with signiﬁcantly higher rates of appropriate initial
antibiotic treatment for pneumonia. Soo Hoo et al. [17] stud-
TABLE 1. Risk factors for infection or colonization related to multidrug-resistant (MDR) bacteria at intensive-care unit (ICU)
admission
MDR bacteria Univariate analysis Multivariate analysisa
Yes
n = 83
No
n = 542 p-Value OR (95% CI) p-Value OR (95% CI)
Age (years) 59 ± 17 55 ± 19 0.095 – – –
Male gender 59 (71) 375 (69) 0.825 1.1 (0.6–1.8) – –
SAPS II 45 ± 21 46 ± 21 0.772 – – –
LOD score 4 ± 3.5 4.8 ± 3.7 0.095 – – –
McCabe score <0.001 – – –
1 25 (30) 270 (49)
2 46 (55) 208 (38)
3 12 (14) 62 (11)
Admission source 0.204 – – –
Direct 26 (31) 218 (40)
Hospital transfer 49 (59) 296 (54)
ICU transfer 8 (9) 27 (4)
Duration of hospitalization before ICU admission (days) 10 ± 2 5 ± 1 <0.001 – – –
Category of admission 0.971 0.9 (0.5–1.6) – –
Medical 62 (74) 402 (74)
Surgical 21 (25) 140 (25)
Comorbidities
Diabetes mellitus 21 (25) 96 (17) 0.134 1.5 (0.9–2.7) – –
COPD 29 (34) 145 (26) 0.156 1.4 (0.9–2.4) – –
Liver cirrhosis 2 (2) 15 (2) >0.999 0.8 (0.1–3.8) – –
Chronic dialysis 4 (4) 15 (2) 0.502 1.7 (0.5–5.5) – –
Immunosuppression 23 (27) 113 (20) 0.205 1.4 (0.7–2.7) – –
Home wound care or home infusion 6 (7) 13 (2) 0.041 3.1 (1.1–8.5) – –
Residence in a nursing home 11 (13) 23 (4) 0.002 3.4 (1.6–7.3) <0.001 2 (1.1–3.7)
Prior hospitalization 43 (51) 126 (23) <0.001 3.5 (2.2–5.7) <0.001 3.9 (1.7–8.8)
Prior antimicrobial treatment 51 (61) 222 (40) 0.001 2.3 (1.4–3.7) 0.008 2.3 (1.2–4.3)
Risk factors for MDR bacteria according to ATS/IDSA guidelines
Yes 74 (89) 328 (62) <0.001 5.3 (2.6–10.9) – –
Number of risk factors 2.1 ± 1.1 1.1 ± 1 <0.001
ATS, American Thoracic Society; COPD, chronic obstructive pulmonary disease; IDSA, Infectious Diseases Society of America; LOD, logistic organ dysfunction; SAPS, simpli-
ﬁed acute physiology score.
Data are presented as mean ± standard deviation or number (%).
aLemeshow goodness-of-ﬁt test, p 0.81.
TABLE 2. Microorganisms associated with infection at
intensive-care unit admission
Pneumonia
n = 88
Other infections
n = 58
All microorganisms 91 64
Multidrug-resistant bacteria 33 (36) 8 (12)
Gram-negative 58 (63) 33 (51)
Pseudomonas aeruginosa 24 (26)a 7 (10)a
Enterobacter sp. 11 (12)b 3 (4)b
Escherichia coli 8 (9)b 14 (21)
Proteus sp. 1 (1) 3 (4)
Citrobacter freundii 5 (5) 2 (3)
Haemophilus inﬂuenzae 5 (5) 0 (0)
Stenotrophomonas maltophilia 5 (5) 0 (0)
Klebsiella oxytoca 2 (2)b 2 (3)b
Serratia sp. 3 (3)b 0 (0)
Other 2 (2) 2 (3)
Gram-positive 33 (36) 27 (42)
Methicillin-sensitive Staphylococcus aureus 12 (13) 6 (9)
Methicillin-resistant Staphylococcus aureus 7 (7) 3 (4)
Streptococcus pneumoniae 14 (15) 1 (1)
Streptococcus sp. 0 (0) 9 (14)
Enterococcus sp. 0 (0) 4 (6)
Other 0 (0) 4 (6)
Other microorganisms 0 (0) 4 (6)
Data are number (%).
aIncluding 11 (45%), and two (28%) resistant to ceftazidime and/or imipenem;
respectively.
bIncluding six (54%), one (33%), two (25%), one (50%), one (50%) and one
(33%) extended-spectrum b-lactamase-producing Gram-negative bacilli, respec-
tively.
TABLE 3. Distribution of multidrug-resistant bacteria
according to screening site
Any
site
Nasal
swab
Rectal
swab
Tracheal
aspirate
Others
All multidrug-resistant bacteria 100 30 35 36 6
Resistant Pseudomonas aeruginosa 25 (25) 3 (10) 7 (20) 15 (41) 2 (33)
Acinetobacter baumannii 9 (9) 2 (6) 6 (17) 2 (5) 0 (0)
Stenotrophomonas maltophilia 7 (7) 1 (3) 0 (0) 5 (13) 1 (16)
Methicillin-resistant
Staphylococcus aureus
30 (30) 22 (73) 2 (5) 6 (16) 1 (16)
Extended-spectrum
b-lactamase-producing
Gram-negative bacilli
29 (29) 2 (6) 20 (57) 8 (22) 2 (5)
More than one
multidrug-resistant
bacterium
12 (12) 1 (3) 3 (8) 3 (8) 0 (0)
Data are number (%).
Some patients had the same multidrug-resistant bacterium at several sites.
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ied the impact of the implementation of the 1996 ATS guide-
lines in 61 episodes of severe nosocomial pneumonia and
compared the ﬁndings with outcomes before application of
this approach. They observed that guideline implementation
resulted in a higher rate of appropriately treated patients
and a lower mortality. A recent study found adherence to
standard operating procedure, adapted to the local resis-
tance rates in the initial empirical treatment of pneumonia,
to be associated with a shorter duration of treatment of the
ﬁrst pneumonia episode, a shorter duration of mechanical
ventilation and a shorter ICU stay [18]. In addition, in previ-
ous studies, performed in patients with community-acquired
pneumonia, non-adherence to guidelines was found to be a
risk factor for mortality [19], longer duration of hospital stay
and mechanical ventilation [20].
De-escalation was performed only in a small proportion
(10%) of patients with suspected infection. However, de-
escalation was performed in 39% of patients with infection
caused by sensitive bacteria, which is in line with previous
studies of patients with ventilator-associated pneumonia
[21–23]. The high rates of negative microbiological results
(61%) and MDR bacteria (28%) could explain these results
[13,21].
In patients with pneumonia, adherence to recent ATS/
IDSA criteria was associated with signiﬁcantly higher rates of
de-escalation. Several studies [24–27] of patients with venti-
lator-associated pneumonia demonstrated that antimicrobial
treatment could be safely stopped or de-escalated according
to microbiological results. However, de-escalation is still
rarely performed in patients with negative microbiological
results. One potential explanation is the association of possi-
ble false-negative cultures with limitations in the sensitivity of
the technique. On the other hand, prolonged antibiotic treat-
ment is a well-known risk factor for the emergence of MDR
bacteria [28,29]. Therefore, de-escalation should be per-
formed in patients with negative microbiological results and
clinical improvement.
Isolation techniques were applied in all patients at ICU
admission. However, only 13% of the study patients were
colonized or infected with MDR bacteria at ICU admission.
The excellent negative predictive value of ATS/IDSA criteria
in predicting MDR bacteria at ICU admission suggests that
isolation techniques at ICU admission could be based on
these criteria. Contact isolation could have been avoided in
36% of study patients, if such a strategy had been applied
(data not shown).
MDR bacteria were identiﬁed in 13% of the study patients
at ICU admission. This result is in line with previous ﬁndings
[30–34]. In about one-third of the study patients with microbi-
ologically conﬁrmed infections, MDR bacteria were the causa-
tive organisms. This result underlines the importance of early
identiﬁcation of these patients in order to provide appropriate
initial antibiotic treatment. Prior antimicrobial treatment, resi-
dence in a nursing home and prior hospitalization were identi-
ﬁed as independent predictors of colonization or infection
with MDR bacteria at ICU admission. All these risk factors
have been identiﬁed in previous studies [31,33,35].
This study has some limitations. Our results may not be
relevant to ICU patients in general, because this study was
performed in a single centre. In addition, the rates of occur-
rence of MDR bacteria are different among institutions and
countries, suggesting that recommendations and procedures
should be based on local data [36]. Furthermore, our study
was observational. Therefore, an interventional study is
needed in order to determine the impact of a contact
isolation strategy based on ATS/IDSA criteria on patient
outcomes.
The rate of prior antibiotic treatment was high (44% of
the study patients). This may have resulted in negative
microbiological cultures in patients with infection at ICU
admission. In addition, no information could be obtained on
the nature of prior antibiotic treatment. Therefore, no rela-
tionship could be determined between exposure to speciﬁc
antibiotics and occurrence of MDR bacteria.
The number of patients with pneumonia was too small to
allow determination of the impact of different categories of
pneumonia on the accuracy of ATS/IDSA criteria. How-
ever, sensitivity and speciﬁcity were similar in patients with
TABLE 4. Accuracy of American Thoracic Society (ATS)/Infectious Diseases Society of America (IDSA) criteria in predicting
colonization or infection related to multidrug-resistant bacteria at intensive-care unit (ICU) admission
All patients Infection Pneumonia
n = 625
Suspected
n = 383
Conﬁrmed
n = 146
Suspected
n = 223
Conﬁrmed
n = 88
Sensitivity, n (%) 74/83 (89) 40/41 (97) 40/41 (97) 32/33 (96) 32/33 (96)
Speciﬁcity, n (%) 214/542 (39) 72/342 (21) 19/105 (18) 43/190 (22) 13/55 (23)
Positive predictive value, n (%) 74/402 (18) 40/310 (12) 40/126 (31) 32/179 (17) 32/74 (43)
Negative predictive value, n (%) 214/223 (96) 72/73 (98) 19/20 (95) 43/44 (97) 13/14 (92)
Positive likelihood ratio 1.4 1.2 1.1 1.2 1.2
Negative likelihood ratio 0.2 0.1 0.1 0.1 0.1
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healthcare-associated and hospital-acquired pneumonia (data
not shown), suggesting that our ﬁndings are applicable to
these subgroups of patients. Finally, ATS/IDSA guidelines
were developed to identify patients with potentially drug-
resistant pathogens. In our study, only proven MDR bacteria
were taken into account. However, we repeated our analysis
of the accuracy of ATS/IDSA criteria in predicting coloniza-
tion or infection with potentially resistant drug-resistant bac-
teria (MRSA, A. baumannii, S. maltophilia, extended-spectrum
b-lactamase-producing Gram-negative bacilli and all P. aeru-
ginosa isolates). Similar sensitivity, speciﬁcity, negative predic-
tive values and positive predictive values were found (data
not shown).
We conclude that ATS/IDSA criteria had an excellent neg-
ative predictive value and a low positive predictive value in
predicting infection or colonization with MDR bacteria at
ICU admission. Adherence to guidelines was associated with
a higher rate of appropriate initial antibiotic treatment. How-
ever, de-escalation should be performed in order to prevent
subsequent emergence of MDR bacteria.
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